# nature portfolio

Corresponding author(s): Zhaomin Zheng and Jianru Wang

Last updated by author(s): Oct 11, 2023

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

### **Statistics**

| For | For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |   |  |  |  |
|-----|---|---|--|--|--|
| n/a | Confirmed   |   |  |  |  |
|     | ×   | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement   |  |  |  |
|     | X   | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly   |  |  |  |
|     | ×   | The statistical test(s) used AND whether they are one- or two-sided<br>Only common tests should be described solely by name; describe more complex techniques in the Methods section.   |  |  |  |
| X   |   | A description of all covariates tested  |  |  |  |
|     | X   | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons   |  |  |  |
|     | ×   | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)<br>AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |  |  |  |
| ×   |   | For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.                           |  |  |  |
| X   |   | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |  |  |  |
| x   |   | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |  |  |  |
| X   |   | Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated  |  |  |  |
|     |   | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.   |  |  |  |
|     |   |   |  |  |  |

### Software and code

Policy information about availability of computer code 1. micro CT image collection: SkyScan 1176 (Bruker, Kartuizersweg, Belgium) Data collection 2. microscopy images of HE, SO and IHC staining: Kfbio/KF-PRO-020 Digital pathological scanner (Zhejiang, China) 2. microscopy images of tissue Immunofluorescence:Olympus BX63 Microscopes( 3. microscopy images of cell Immunofluorescence analysis: confocal microscope( Lecia, Germany) 3.RT-qPCR data collection: Applied Biosystems 7500 Sequencing Detection System (version. 2.3; Foster City, CA, USA) 4. Flow Cytometer: Beckman CytExpert analyzer. 5. Western blot images: Tanon 4600 (Shanghai, China) Data analysis We used GraphPad Prism (version 8.0) for statistical analysis; FlowJo v10.8.1 for flow cytometry analysis; ImageJ 1.50i for microscopy images analysis; SkyScan1276 CTAn for disc height analysis; Alphafold 2 for Serglycin protein structure predicted; AutodockTools\_1.5.6 and Pymol v1.8 for molecular docking. scRNA-seq data analysis was performed by NovelBio Bio-Pharm Technology Co., Ltd. with NovelBrain Cloud Analysis Platform. Cytokine Array analysis was performed by The RayBio<sup>®</sup> Analysis Tool (RayBio<sup>®</sup>, Norcross, GA) RNA-seq analysis was performed by Guangzhou Epibiotek Co., Ltd., Guangzhou, China the package are follows:

HISAT2 (version 2 2.1.0): https://daehwankimlab.github.io/hisat2/download/#version-hisat2-210 Htseq (Version 0.11.0): https://htseq.readthedocs.io/en/release\_0.11.1/install.html DESeq2 (1.22.2):https://bioconductor.org/packages/release/bioc/html/DESeq2.html ggplot2: https://cran.r-project.org/web/packages/ggplot2/index.html sankey plot: https://r-charts.com/flow/sankey-diagram-ggplot2/ Venn plot: ggsankey packages: https://r-charts.com/part-whole/ggvenndiagram/ Circos Plot: ggVennDiagram packages : https://cran.r-project.org/web/packages/RCircos/ corrplot: corrplot packages: https://cran.r-project.org/web/packages/corrplot/index.html

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that the data supporting the findings of this study are available with the paper and its Supplementary information files. All data are available in the main text or the materials. The raw sequence data reported in this paper have been deposited in the GEO database under accession code GSE244889(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE244889). The data supporting the findings of this study are available from the corresponding authors upon reasonable request. Source data are provided with this paper.

### Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

| Reporting on sex and gender | No sex- and gender-based analyses have been performed.<br>there was no significant statistical significance between the male and female for the incidence rate of intervertebral disc<br>degeneration   |
|-----------------------------|---|
| Population characteristics  | Human NP tissue samples were collected from patients (19 females and 29 males, age 10-85 years old) undergoing NP removal. The degree of disc degeneration was evaluated according to the Pfirrmann grading system. Normal IVDs were obtained from patients who had experienced trauma, and degenerated IVDs were obtained from patients with degenerative spinal diseases (disc herniation, spinal canal stenosis, and degenerative scoliosis).  |
| Recruitment                 | All the patients signed an informed consent form. NP samples from Pfirrmann grade I-II were included into the mild degenerated discs (MDD) group; samples from Pfirrmann grade III-V were included into the severe degenerative discs (SDD) group. The information of human NP samples were listed in the supplementary tables. Between September 2016 and June 2021, we collected 48 IVD samples from patients (19 females and 29 males, age 10-85 years old). Detailed information on the specimens is shown in Table S2. |
| Ethics oversight            | This study protocol of using patient samples was approved by the Ethics Committee of The First Affiliated Hospital of Sun Yat-<br>sen University.   |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Field-specific reporting

**×** Life sciences

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

📃 Behavioural & social sciences 📃 Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size     | Sample size was chosen to ensure an adequate statistical power. For in vitro study, 5 biological replicates were used. The number of animal were described in the manuscript. |
|-----------------|---|
| Data exclusions | Samples lacking Intervertebral disc tissue in the spine slide were excluded for the tissue analysis   |
| Replication     | All experimental findings were reproduced in dependently as least three times. The number of biologically independent samples, mice per                                       |

nature portfolio | reporting summary

group, or human specimens were listed in the figure legend. Quantitative data shown as mean  $\pm$  s.d.

| Randomization | Human or mouse NP tissue were randomly assigned to each experimental group. Animals were also randomly assigned to each experimental group                         |
|---------------|--|
|               |  |
| Blinding      | Pfirrmann grade, H&E score evaluation, disc height evaluation were performed by individuals who were blinded to the specific conditions of the experimental group. |

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems |                                | Methods |                        |
|----------------------------------|--------------------------------|---------|------------------------|
| n/a                              | Involved in the study          | n/a     | Involved in the study  |
|                                  | X Antibodies                   | ×       | ChIP-seq               |
|                                  | <b>X</b> Eukaryotic cell lines |         | Flow cytometry         |
| ×                                | Palaeontology and archaeology  | ×       | MRI-based neuroimaging |
|                                  | X Animals and other organisms  |         |                        |
| ×                                | Clinical data                  |         |                        |
| ×                                | Dual use research of concern   |         |                        |

### Antibodies

Antibodies used

All antibodies used in this study are detailed in material and methods section. The detailed information: (also listed in supplementary tables) Primary antibody UBE2C Bioss Antibodies bs-8357R IHC 1:100 FBLN1 Bioss Antibodies bs-0809R IHC 1:100 IF 1:100 CHI3L2 Bioss Antibodies bs-12358R IHC 1:100 DKK1 Bioss Antibodies bs-2162R IHC 1:100 MSMO1 Abcam ab203587 IHC 1:200 CP Bioss Antibodies bs-2373R IHC 1:100 SRGN Santa Cruz HPA000759 IHC 1:200 IF 1:100 SRGN Abcam ab156991 (not available) WB 1:1000 SRGN Sigma-Aldrich SAB2103016 WB 1:1000 COL 1 Bioss Antibodies bs-10423R IHC 1:100 IF 1:100 COL 2 Cell Signaling Technology 13141 ACAN Cell Signaling Technology 3033 IHC 1:100 IF 1:100 IL-1β Abcam ab254360 WB 1:1000 IF 1:50 IL-1β Abcam ab283818 IHC 1:200 CCL3 Abcam ab259372 WB 1:1000 IHC 1:200 IF 1:500 TNF-α Abcam ab183218 WB 1:1000 TNF-α Abcam ab1793 IHC 1:200 IF 1:100 IKBα Abcam ab32518 WB 1:1000 p- IKBα Abcam ab133462 WB 1: 1000 pan-AKT Abcam ab8805 WB 1: 1000 p-AKT Abcam ab8933 WB 1: 1000 Smad2 Abcam ab40855 WB 1: 1000 p-Smad2 Abcam ab280888 WB 1: 1000 Smad3 Abcam ab40854 WB 1: 1000 p-Smad3 Abcam ab52903 WB 1: 1000 ERK1/2 Abcam ab184699 WB 1: 1000 p-ERK1/2 Abcam ab201015 WB 1: 1000 p65 Abcam ab16502 WB 1:1000 p-p65 Santa Cruz sc-136548 WB 1:1000 IF 1:100 p50/p105 Abcam ab305263 WB 1: 1000 p52/ p100 Santa Cruz sc-7386 WB 1: 1000 cRel Abcam ab133251 WB 1: 1000 RelB Abcam ab33907 WB 1:1000 F4/80 Bioss Antibodies bsm-34028M IHC 1:100 IF 1:100 CD86 Bioss Antibodies bs-1035R IF 1:100 Beta Tubulin (HRP conjugated) Bioss Antibodies bsm-52847R WB 1:5000

March 2021

#### Secondary antibody

Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technology 7074S WB 1:5000 Anti-mouse IgG, HRP-linked Antibody Cell Signaling Technology 7076S WB 1:5000 Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488 Thermo Fisher Scientific A-11008 IF 1:2000 Goat anti-mouse IgG (H+L) Secondary Antibody, DyLight™ 488 Thermo Fisher Scientific A-10680 IF 1:2000 Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 555 Thermo Fisher Scientific A-21429 IF 1:2000 Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 555 Thermo Fisher Scientific A-21429 IF 1:2000 Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 594 Thermo Fisher Scientific R-37117 IF 1:2000 Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647 Thermo Fisher Scientific A-21245 IF 1:2000

Validation

All antibodies used in this study were validated by the supplier as follows: Rabbit anti-UBE2C IHC bs-8357R Bioss Antibodies https://www.biossantibodies.com/datasheets/bs-8357R Rabbit anti-Fibulin1(FBLN1) IHC/IF bs-0809R Bioss Antibodies https://www.biossantibodies.com/datasheets/bs-0809R

Rabbit anti-CHI3L2 IHC bs-12358R Bioss Antibodies

https://www.biossantibodies.com/datasheets/bs-12358R

Rabbit anti-DKK1 IHC bs-2162R Bioss Antibodies

https://www.biossantibodies.com/datasheets/bs-2162R

Rabbit anti-MSMO1 IHC ab203587 Abcam

https://www.abcam.com/products/primary-antibodies/c-4-methylsterol-oxidasesc4mol-antibody-ab203587.html

Rabbit Anti-Ceruloplasmin IHC bs-2373R Bioss Antibodies

http://www.bioss.com.cn/prolook\_03.asp?id=AF08169606003634&pro37=1

Mouse anti-SRGN IHC/IF sc-374657 Santa Cruz

https://www.scbt.com/p/serglycin-antibody-c-11?requestFrom=search

Rabbit anti-Serglycin WB ab156991 (not available) Abcam

https://www.abcam.com/products/primary-antibodies/serglycin-antibody-ab156991.html

Rabbit anti-SRGN WB SAB2103016 Sigma-Aldrich

https://www.sigmaaldrich.cn/CN/zh/product/sigma/sab2103016

Mouse anti-Collagen 1 IHC/IF bs-10423R Bioss Antibodies

https://www.biossusa.com/products/bs-10423r

Rabbit anti-COL2A1 WB #43306 Cell Signaling Technology

https://www.cellsignal.com/products/primary-antibodies/col2a1-e8s2s-rabbit-mab/43306?

\_=1695578024504&Ntt=col2&tahead=true

Rabbit anti-aggrecan WB #28971 Cell Signaling Technology

https://www.cellsignal.com/products/primary-antibodies/aggrecan-e8b8s-rabbit-mab/28971?

\_=1695578037273&Ntt=ACAN&tahead=true

Rabbit anti-IL-1 beta WB/IF ab254360 Abcam

https://www.abcam.com/products/primary-antibodies/il-1-beta-antibody-epr23851-127-ab254360.html

Rabbit anti-IL-1 beta IHC ab283818 Abcam https://www.abcam.com/products/primary-antibodies/il-1-beta-antibody-rm1009-ab283818.html

Rabbit anti-CCL3 WB/IHC/IF ab259372 Abcam

https://www.abcam.com/products/primary-antibodies/macrophage-inflammatory-protein-1-alpha--ccl3--ccl3l1-antibody-epr23751-54-ab259372.html

Rabbit anti-TNF alpha WB ab183218 Abcam

https://www.abcam.com/products/primary-antibodies/tnf-alpha-antibody-epr19147-ab183218.html

Mouse anti-TNF alpha IHC/IF ab1793 Abcam https://www.abcam.com/products/primary-antibodies/tnf-alpha-antibody-52b83-ab1793.html

Rabbit anti-IKB alpha WB ab32518 Abcam

https://www.abcam.com/products/primary-antibodies/ikb-alpha-antibody-e130-ab32518.html

Rabbit anti-IKB alpha (phospho S36) WB ab133462 Abcam

https://www.abcam.com/products/primary-antibodies/ikb-alpha-phospho-s36-antibody-epr62352-ab133462.html Rabbit anti-pan-AKT WB ab8805 Abcam

https://www.abcam.com/products/primary-antibodies/pan-akt-antibody-ab8805.html

Rabbit anti-pan-AKT(phospho T308) WB ab8933 Abcam

https://www.abcam.com/products/primary-antibodies/pan-akt-phospho-t308-antibody-ab8933.html Rabbit anti-Smad2 WB ab40855 Abcam

https://www.abcam.com/products/primary-antibodies/smad2-antibody-ep784y-ab40855.html

Rabbit anti-Smad2(phospho S467) WB ab280888 Abcam

https://www.abcam.com/products/primary-antibodies/smad2-phospho-s467-antibody-epr23681-40-ab280888.html Rabbit anti-Smad3 WB ab40854 Abcam

https://www.abcam.com/products/primary-antibodies/smad3-antibody-ep568y-ab40854.html

Rabbit anti-Smad3(phospho S423+S425) WB ab52903 Abcam

https://www.abcam.com/products/primary-antibodies/smad3-phospho-s423--s425-antibody-ep823y-ab52903.html Rabbit anti-ERK1+ERK2 WB ab184699 Abcam https://www.abcam.com/products/primary-antibodies/erk1--erk2-antibody-epr17526-ab184699.html Rabbit anti-ERK1(phospho T202)+ERK2(phospho T185) WB ab201015 Abcam https://www.abcam.com/products/primary-antibodies/erk1-phospho-t202--erk2-phospho-t185-antibody-epr19401-ab201015.html Rabbit anti-NF-kB p65 WB ab16502 Abcam https://www.abcam.com/products/primary-antibodies/nf-kb-p65-antibody-ab16502.html Mouse anti-p-NF-kB p65 WB/IF sc-136548 Santa Cruz https://www.scbt.com/p/p-nfkappab-p65-antibody-27-ser-536?productCanUrl=p-nfkappab-p65-antibody-27ser-536&\_requestid=2944471 Mouse anti-NFkB p105/p50 WB ab305263 Abcam https://www.abcam.com/products/primary-antibodies/nfkb-p105--p50-antibody-1298ct792105117133-ab305263.html Mouse anti-NFkB p52/p100/NFKB2 WB sc-7386 Santa Cruz https://www.scbt.com/p/nfkappab-p52-antibody-c-5?requestFrom=search Rabbit anti-c-Rel WB ab133251 Abcam https://www.abcam.com/products/primary-antibodies/c-rel-antibody-epr25592-ab133251.html Rabbit anti-Rel B WB ab33907 Abcam https://www.abcam.com/products/primary-antibodies/rel-b-antibody-ep614y-ab33907.html Mouse anti-ADGRE1(F4/80) IHC/IF bsm-34028M Bioss Antibodies http://www.bioss.com.cn/SpeNew01.asp?id=214469&pro37=1&pro33=101&guige01=100ul Rabbit anti-CD86 IF bs-1035R Bioss Antibodies https://www.biossantibodies.com/datasheets/bs-1035R Rabbit anti-beta Tubulin (HRP conjugated) WB bsm-52847R Bioss Antibodies https://www.biossantibodies.com/datasheets/bsm-52847R Mouse anti-CD11c PE-Cyanine7 Flow Cytometry 25-0114-81 eBioScience https://www.thermofisher.cn/cn/zh/antibody/product/CD11c-Antibody-clone-N418-Monoclonal/25-0114-81 Mouse anti-CD86-PB450 Flow Cytometry 48-0862-80 eBioScience https://www.thermofisher.cn/cn/zh/antibody/product/CD86-B7-2-Antibody-clone-GL1-Monoclonal/48-0862-80 Anti-rabbit IgG, HRP-linked Antibody WB #7074 Cell Signaling Technology https://www.cellsignal.com/products/secondary-antibodies/anti-rabbit-igg-hrp-linked-antibody/7074?site-searchtype=Products&N=4294956287&Ntt=7074s&fromPage=plp&\_requestid=3557248 Anti-mouse IgG, HRP-linked Antibody WB #7076 Cell Signaling Technology https://www.cellsignal.com/products/secondary-antibodies/anti-mouse-igg-hrp-linked-antibody/7076?site-searchtype=Products&N=4294956287&Ntt=7076s&fromPage=plp&\_requestid=3557493 Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488 IF A-11008 Thermo Fisher Scientific https://www.thermofisher.cn/cn/zh/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/ A-11008 Goat anti-Mouse IgG, IgM (H+L) Secondary Antibody, Alexa Fluor™ 488 IF A-10680 Thermo Fisher Scientific https://www.thermofisher.cn/cn/zh/antibody/product/Goat-anti-Mouse-IgG-IgM-H-L-Secondary-Antibody-Polyclonal/A-10680 Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 555 IF A-21429 Thermo Fisher Scientific https://www.thermofisher.cn/cn/zh/antibody/product/Goat-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21429 Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 594 IF R-37117 Thermo Fisher Scientific https://www.thermofisher.cn/cn/zh/antibody/product/Goat-anti-Rabbit-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/ R37117 Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647 IF A-21245 Thermo Fisher Scientific https://www.thermofisher.cn/cn/zh/antibody/product/Goat-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-

### Eukaryotic cell lines

Polyclonal/A-21245

| Policy information about cell lines and Sex and Gender in Research |   |  |  |  |  |
|--|---|--|--|--|--|
| Cell line source(s)  | The RAW264.7 cells in this study was obtained from Sunncell Biotech (Cat#. SNL-112, Wuhan, China).  |  |  |  |  |
| Authentication   | The Raw264.7 cells were authenticated by STR authentication(Cell line STR authentication report is provided in Supplementary Table S7) in Sunncell Biotech before obtained, and subsequent authentication was conducted through morphology checks and growth curve analysis during the cultivation process. |  |  |  |  |
| Mycoplasma contamination   | Cell lines were routinely tested and found negative for mycoplasma infection by the vender.   |  |  |  |  |
| Commonly misidentified lines<br>(See <u>ICLAC</u> register)        | None of the cell lines used in this study is found in the database of commonly misidentified cell lines.  |  |  |  |  |

### Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Animal study was conducted by 7-8 weeks Srgn knockout C57BL/6 (n = 5 per group), which were purchased from Cyagen Biosciences Inc (Suzhou, China). All mice were raised in SPF environment under constant temperature (23-25°C) and humidity (50%) with a 12hour light/12-hour dark circadian cycle. the method of Srgn knockout mice construction: the gRNA for the mouse SRGN gene and Cas9 mRNA were coinjected into fertilized mouse eggs to generate targeted knockout offspring. F2 founder animals were identified by PCR (Supplementary Fig. S5 a-f), followed by sequencing analysis. Heterozygous mice were then bred to assess germline transmission and F3 animal generation. Wild animals This study did not involved wild animals Reporting on sex No sex- and gender-based analyses have been performed. Field-collected samples The study did not involve samples collected from the field. Protocol of animal model of intradiscal injection was approved by The Institutional Animal Care and Use Committee (IACUC) at The Ethics oversight First Affiliated Hospital of Sun Yat-sen University (No. [2020]017).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Flow Cytometry

#### Plots

Confirm that:

**X** The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

🗴 The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

**X** All plots are contour plots with outliers or pseudocolor plots.

**X** A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

| Sample preparation        | The treated RAW264.7 cells were concentrated, washed with PBS twice. After washing, cells were incubated with fluorescence-labeled surface Abs against CD11c and CD86 (eBioscience) for 30min at 4°C.Fluorescence signals were detected using the Beckman CytoFLEX Flow Cytometer.      |
|---------------------------|---|
| Instrument                | Cytoflex, Beckman Coulter, Inc.   |
| Software                  | CytExpert analyzer  |
| Cell population abundance | CytExpert analyzer for data collection. FlowJo software for data analysis.  |
| Gating strategy           | All samples were initially gated using forward scatter and side scatter to identify events corresponding to cells or, alternatively by CD11c and CD86 to identify events corresponding to M1 macrophages. The follow gating steps are presented in principal and supplementary figures. |

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.